Adaptive Biotechnologies

ISIN US00650F1093

 | 

WKN A2PLR5

Market cap (in EUR)
3.475 m
Country
Verenigde Staten
Sector
Gezondheidszorg
Dividend yield
0,00%
 

Overview

Description

Adaptive Biotechnologies Corp. houdt zich bezig met de ontwikkeling van een immuungeneesmiddelenplatform. Haar producten en diensten omvatten immunoSEQ, clonoSEQ, cellulaire therapie en vaccins. Het bedrijf werd op 8 september 2009 opgericht door Chad Robins, Harlan Robins en Chris Carlson en heeft zijn hoofdkantoor in Seattle, WA.
Show more Show less
Gezondheidszorg Gezondheidszorg Diensten Diversen Gezondheidszorg Verenigde Staten

Financials

Key metrics

Market capitalisation, EUR 3.475 m
EPS, EUR -0,35
P/B ratio 28,3
P/E ratio -
Dividend yield 0,00%

Income statement (2025)

Revenue, EUR 246 m
Net income, EUR -53 m
Profit margin -21,48%

What ETF is Adaptive Biotechnologies in?

There are 4 ETFs which contain Adaptive Biotechnologies. All of these ETFs are listed in the table below. The ETF with the largest weighting of Adaptive Biotechnologies is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
ETF Weight Investment focus Fund size (in m EUR)
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0,24%
Equity
United States
Health Care
Biotech
72
Vanguard Russell 2000 U.S. Small-Cap UCITS ETF USD Dist 0,09%
Equity
United States
Small Cap
3
WisdomTree Russell 2000 0,09%
Equity
United States
Small Cap
7
JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist) 0,04%
Equity
United States
Small Cap
231
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.